Skip to main content
. 2023 Jun 24;9(7):e17386. doi: 10.1016/j.heliyon.2023.e17386

Fig. 4.

Fig. 4

The AURKA-YBX1/hnRNPK complex is associated with poor prognosis in breast cancer. (A) AURKA mRNA expression analysis in clinical breast cancer and normal tissues from GEPIA. Tumor: 1085; Normal: 112. (B) Correlation analysis of AURKA mRNA expression with relapse free survival (RFS) and post progression survival (PPS) in clinical breast cancer specimens using GEPIA. Total number of patients in the RFS group, 7816; total number of patients in the PPS group, 554. (C) Correlation analysis of YBX1 protein expression with overall survival (OS) in clinical breast cancer specimens using Kaplan-Meier Plotter. n = 108. (D) Correlation analysis of YBX1 mRNA expression with OS in clinical breast cancer specimens using Kaplan-Meier Plotter. n = 9409. (E) Correlation analysis of hnRNPK protein expression with OS in clinical breast cancer specimens using Kaplan-Meier Plotter. n = 108. (F) Correlation analysis of hnRNPK mRNA expression with RFS and PPS in clinical breast cancer specimens using GEPIA. Total number of patients in the RFS group, 7816; total number of patients in the PPS group, 554. (G) AURKA and hnRNPK protein expression in breast cancer specimens (n = 12; T: tumor) was subjected to Western blot analysis. AURKA and hnRNPK expression levels were normalized to GAPDH and the results of linear regression analysis are shown. R2 = 0.9308, P < 0.0001.